Zuo L, Wang M, Hou F, Yan Y, Chen N, Qian J, Wang M, Bieber B, Pisoni RL, Robinson BM, Anand S. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study.
Blood Purif 2016;
42:33-43. [PMID:
27045519 PMCID:
PMC4919113 DOI:
10.1159/000442741]
[Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Accepted: 11/25/2015] [Indexed: 02/05/2023]
Abstract
BACKGROUND
As the utilization of hemodialysis increases in China, it is critical to examine anemia management.
METHODS
Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies.
RESULTS
Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12.
CONCLUSION
A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741.
Collapse